Welgene Biotech Co.,Ltd. (TPEX:6661)

Welgene Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	168.29	224.33	173.5	188.13	158.59	199.77
Short-Term Investments	33	43	53	9	59	21
Trading Asset Securities	-	-	-	-	-	2.72
Cash & Short-Term Investments	201.29	267.33	226.5	197.13	217.59	223.49
Cash Growth	-14.05%	18.03%	14.90%	-9.40%	-2.64%	23.24%
Accounts Receivable	40.75	46.7	45.58	46.98	46.57	82.86
Other Receivables	0.41	1.4	3.61	3.24	0.75	4.28
Receivables	41.16	48.09	49.19	50.23	47.31	87.14
Inventory	55.63	39.08	36.88	53.77	33.98	26.99
Prepaid Expenses	2.56	4.63	5.96	4.45	2.46	2.74
Other Current Assets	6.27	4.69	5.32	0.71	0.86	0.77
Total Current Assets	306.9	363.83	323.84	306.28	302.2	341.13
Property, Plant & Equipment	309.31	234.45	174.88	198.82	78.63	30.67
Long-Term Investments	17.45	17.61	26.12	33.98	42.09	41.36
Other Intangible Assets	16.27	0.65	0.16	0.39	0.73	1.07
Long-Term Deferred Tax Assets	0.58	0.51	0.44	0.56	0.49	0.69
Other Long-Term Assets	8.09	5.15	2.8	8.13	11.57	9.62
Total Assets	658.59	622.19	528.25	548.16	435.71	424.54

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	26.95	25.17	16.91	17.37	18.99	12.53
Accrued Expenses	16.9	25.43	24.28	21.18	25.02	26.61
Short-Term Debt	15	12	9	11	11.21	12.56
Current Portion of Long-Term Debt	31.31	28.04	11.68	11.05	-	-
Current Portion of Leases	14.74	14.55	13.58	13.33	13.08	11.28
Current Income Taxes Payable	-	-	0.36	-	2.44	-
Current Unearned Revenue	45.63	54.2	56.13	46.18	29.45	46.53
Other Current Liabilities	9.98	5.02	4.66	7.84	4.51	4.71
Total Current Liabilities	160.51	164.4	136.59	127.94	104.71	114.22
Long-Term Debt	197.28	141.19	95.58	105.4	-	-
Long-Term Leases	22.84	30.25	-	13.58	26.9	-
Pension & Post-Retirement Benefits	-	-	-	-	0.12	0.24
Long-Term Deferred Tax Liabilities	0.26	0.26	0.32	0.3	0.03	0.02
Other Long-Term Liabilities	0.08	0.02	0.02	0.68	-	-
Total Liabilities	380.96	336.12	232.5	247.89	131.76	114.47

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	233.04	233.04	233.04	233.04	233.04	233.04
Additional Paid-In Capital	50.93	50.93	50.86	50.86	50.86	50.86
Retained Earnings	13.3	21.29	20.62	19.51	27.18	28.88
Comprehensive Income & Other	-24.14	-23.97	-16.61	-11.38	-7.32	-2.92
Total Common Equity	273.14	281.3	287.91	292.03	303.76	309.86
Minority Interest	4.49	4.78	7.84	8.24	0.2	0.21
Shareholders' Equity	277.63	286.07	295.75	300.27	303.95	310.06
Total Liabilities & Equity	658.59	622.19	528.25	548.16	435.71	424.54

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	281.15	226.03	129.83	154.35	51.19	23.84
Net Cash (Debt)	-79.87	41.31	96.66	42.78	166.4	199.64
Net Cash Growth	-	-57.27%	125.94%	-74.29%	-16.65%	31.38%
Net Cash Per Share	-3.43	1.77	4.15	1.84	7.13	8.64
Filing Date Shares Outstanding	23.3	23.3	23.3	23.3	23.3	23.3
Total Common Shares Outstanding	23.3	23.3	23.3	23.3	23.3	23.3
Working Capital	146.39	199.43	187.25	178.34	197.49	226.92
Book Value Per Share	11.72	12.07	12.35	12.53	13.03	13.30
Tangible Book Value	256.87	280.65	287.75	291.64	303.03	308.79
Tangible Book Value Per Share	11.02	12.04	12.35	12.51	13.00	13.25
Land	87.3	22.76	22.76	22.76	-	-
Buildings	124.04	97.7	97.7	97.7	-	-
Machinery	125.95	126.84	93.49	107.46	77.2	55.9

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error